Management of Type 2 Diabetes in Patients with Chronic Kidney Disease

First-Line Therapy

For patients with type 2 diabetes and CKD with eGFR ≥30 mL/min/1.73 m², the American College of Cardiology recommends metformin and an SGLT2 inhibitor as first-line therapy, providing both glycemic control and documented cardiovascular and renal protection 1, 2, 3
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that metformin should be used with caution in patients with eGFR <45 mL/min/1.73 m², and avoided in those with eGFR <30 mL/min/1.73 m² 1, 2

For patients with eGFR ≥60 mL/min/1.73 m², the standard dosing of metformin is recommended, with a maximum dose of 2550 mg/day 1, 2
For patients with eGFR 45-59 mL/min/1.73 m², the American Diabetes Association recommends initiating metformin at half the standard dose and titrating to half of the maximum recommended dose, with monitoring of kidney function every 3-6 months 1, 2

For patients with eGFR ≥30 mL/min/1.73 m², the American Heart Association recommends initiating an SGLT2 inhibitor, prioritizing agents with documented kidney or cardiovascular benefits, such as canagliflozin or empagliflozin 1, 2
The European Association for the Study of Diabetes suggests that SGLT2 inhibitors can be continued in patients with eGFR <30 mL/min/1.73 m² if already on therapy and well-tolerated, unless kidney replacement therapy is imminent 5, 1, 6

For patients not achieving glycemic targets despite metformin and SGLT2 inhibitor, or unable to use these medications, the American Association of Clinical Endocrinologists recommends adding a long-acting GLP-1 receptor agonist, which reduces cardiovascular events and preserves eGFR 5, 6
The International Society for Pediatric and Adolescent Diabetes suggests that DPP-4 inhibitors, such as linagliptin, can be used in patients with CKD, with no dose adjustment required across all stages of CKD, including dialysis 1

Patients with CKD stages 3-5 have a markedly increased hypoglycemia risk due to decreased drug clearance and impaired renal gluconeogenesis, according to the National Kidney Foundation 4, 7
To minimize hypoglycemia, the American Diabetes Association recommends prioritizing agents with low hypoglycemia risk, such as metformin, SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors, over sulfonylureas and insulin 3

For patients with eGFR ≥60 mL/min/1.73 m², the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend monitoring kidney function at least annually 1, 2
For patients with eGFR <60 mL/min/1.73 m², the American College of Cardiology suggests monitoring kidney function every 3-6 months 1, 2